Viewing Study NCT04191135

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:04 PM
Ignite Modification Date: 2026-01-02 @ 11:36 PM
Study NCT ID: NCT04191135
Status: COMPLETED
Last Update Posted: 2025-12-08
First Post: 2019-12-05
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Triple Negative Breast Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death Receptor 1 (PD-1, PD1) View
None Programmed Cell Death Receptor Ligand 1 (PD-L1, PDL1) View
None Programmed Cell Death Receptor Ligand 2 (PD-L2, PDL2) View